Actinium begins new Actimab-A trial combining Venetoclax and ASTX-727 to treat patients newly diagnosed with AML in partnership with NCI

Reuters
11 Mar
March 11 (Reuters) - Actinium Pharmaceuticals Inc ::
*ACTINIUM PHARMACEUTICALS ANNOUNCES INITIATION OF ACTIMAB-A TRIPLET COMBINATION FRONTLINE TRIAL UNDER NCI CRADA WITH VENETOCLAX AND TAIHO ONCOLOGY'S HYPOMETHYLATING AGENT ASTX-727 IN PATIENTS WITH NEWLY DIAGNOSED AML

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 11-MAR-202512:30:10.913 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10